跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,604 条关于
“Catalent Indiana”
全部
1,604
临床试验
789
药物
77
机构
158
资讯
580
12个月前
FDA Issues Complete Response Letter for Scholar Rock's Apitegromab Due to Manufacturing Issues
9个月前
Scholar Rock Faces Manufacturing Setback as FDA Issues Warning Letter to Catalent Partner Ahead of Apitegromab Launch
上个月
Scholar Rock Advances Apitegromab Toward September 30 PDUFA Date as First Muscle-Targeted Therapy for SMA
去年
FDA Issues Second Rejection for Regeneron's Lymphoma Therapy Odronextamab Due to Manufacturing Issues
去年
FDA Issues Second Complete Response Letter for Odronextamab in Relapsed/Refractory Follicular Lymphoma
去年
European Commission Approves Novo Holdings' $16.5B Catalent Acquisition
去年
FDA Inspection Reveals Contamination Issues at Novo Nordisk's Indiana Manufacturing Plant
2年前
Siren Biotechnology Partners with Catalent to Advance AAV Immuno-Gene Therapies for Cancer
去年
GenSight Biologics Successfully Transfers LUMEVOQ Manufacturing to Catalent for LHON Gene Therapy
去年
Jupiter Neurosciences Teams with Catalent to Manufacture JOTROL for Parkinson's Disease Trial
第 1 页,共 58 页
上一页
下一页